Tag archive for ‘XmAb20717’
By pharmanewsdaily On Sunday, July 15th, 2018
0 Comments

Xencor launches phase 1 trial of XmAb20717 in advanced solid tumors

Xencor has launched a phase 1 clinical trial of its bispecific antibody XmAb20717, which is being developed for the treatment of multiple advanced solid tumors. The California-based biopharma company has dosed the More...